BRISTOL-MYERS SQUIBB COMPANY vs GILEAD SCIENCES, INC., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and GILD diverge most: on net margin, BMY reads 18.9% and GILD reads -10.6%; on return on equity, BMY reads 41.6% and GILD reads -27.4%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BMY | GILD |
|---|---|---|
| Price | $59.11 | $151.17 |
| Market cap | $121.1B | $187.9B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| P/E | 13.0 | — |
| P/B | 5.42 | 15.89 |
| P/S | 2.46 | 6.17 |
| EV/EBITDA | 47.8 | 19.4 |
| Revenue growth | +3.1% | +5.6% |
| Operating margin | — | -133.2% |
| Net margin | 18.9% | -10.6% |
| Return on equity | 41.6% | -27.4% |
| Return on assets | 10.6% | -6.6% |
| Return on invested capital | — | 21.8% |
| FCF yield | 9.4% | 6.9% |
| Dividend yield | 4.2% | 2.1% |
| Debt / equity | 1.97 | 2.22 |
| Current ratio | 1.53 | 1.27 |
| Altman Z (solvency) | 2.13 | 6.06 |
| Piotroski F (quality) | 8 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.